Huober J, Bertram B, Petru E, Kaufmann M, Schmähl D
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Breast Cancer Res Treat. 1991 Mar;18(1):43-8. doi: 10.1007/BF01975442.
There may exist an association between the genetically determined oxidation status of the antihypertensive agent debrisoquine (DEB) and the propensity to develop tumours. The metabolism of DEB is extensive in 90% of healthy subjects (metabolic ratio = MR = 0-12.6; MR = % DEB excreted divided by % 4-hydroxy-DEB excreted) and poor in 10% (MR greater than 12.6). In patients with cancer of the lung, urinary bladder, and gastrointestinum, the percentage of high metabolizers is increased to greater than 98%. The poor metabolizer mode is almost devoid of cancer patients. It was investigated whether breast cancer patients show a similar association with respect to the oxidative status of DEB. 108 breast cancer patients and 123 women with benign gynecologic disorders received 1 tablet of 10 mg DEB orally in the evening. Urine was collected for the subsequent 8 hrs and analysed for its content of DEB and its main urinary metabolite 4-OH-DEB by means of HPLC. No decreased amount of poor metabolizers was seen in the cancer group.
降压药异喹胍（DEB）的遗传决定氧化状态与患肿瘤倾向之间可能存在关联。在90%的健康受试者中，DEB的代谢广泛（代谢率=MR=0 - 12.6；MR=%排泄的DEB除以%排泄的4 - 羟基DEB），而在10%的健康受试者中代谢较差（MR大于12.6）。在肺癌、膀胱癌和胃肠道癌患者中，强代谢者的百分比增加到98%以上。弱代谢者模式的癌症患者几乎没有。研究了乳腺癌患者在DEB氧化状态方面是否存在类似关联。108名乳腺癌患者和123名患有良性妇科疾病的女性在晚上口服1片10毫克的DEB。随后8小时收集尿液，并通过高效液相色谱法分析尿液中DEB及其主要尿液代谢物4 - OH - DEB的含量。在癌症组中未发现弱代谢者数量减少。
